Skip to main content

Health Report: Roche sets sights on Novartis, Biogen as SMA trial hits target.

2-3 minutos - Source: Reuters

FILE PHOTO: The logo of Swiss drugmaker Roche is seen at its headquarters in Basel, Switzerland February 1, 2018. REUTERS/Arnd Wiegmann
ZURICH (Reuters) - Roche’s bid to rival Biogen and Novartis in treating spinal muscular atrophy (SMA) got a lift on Monday when the Swiss drugmaker said its drug risdiplam improved motor function of patients in a key study.
Roche, which plans to seek approval for the investigational medicine this year, said its SUNFISH trial demonstrated statistically significant improvements in patients aged 2-25 years with Type 2 or 3 SMA, compared to a placebo.
The muscle-wasting disease, which hits 1 in every 10-11,000 newborns, has been a target of significant interest as drugmakers move into a rare disease area that commands ultra-high prices. Biogen’s Spinraza, approved in 2016, lists at $750,000 in year one and $375,000 thereafter, while Novartis’s Zolgensma is the costliest one-time treatment at $2.1 million.
Roche’s risdiplam, which would be the third treatment to market, is taken by mouth, as opposed to injected into the spine like Spinraza. Roche is also hoping data from its studies stacks up to that of Zolgensma, including in older SMA patients with forms of the disease that may emerge months after their birth but leave them with profound disabilities.
In its statement, Roche underscored the safety profile of Risdiplam just weeks after Novartis’s trial of Zolgensma in a similar population of SMA patients was halted by the U.S. Food and Drug Administration when primate study raised concerns of possible nerve damage or loss.
“No treatment related safety findings leading to study withdrawal have been seen in any risdiplam trial to date,” Roche said, adding it would release specific data from the SUNFISH trial at an upcoming medical conference.
Roche has partnered on risdiplam with PTC Therapeutics.
Reporting by John Miller, editing by John Revill


Popular posts from this blog

Analysis | The Cybersecurity 202: How the shutdown could make it harder for the government to retain cybersecurity talent

By Joseph Marks 13-17 minutes THE KEY President Trump delivers an address about border security amid a partial government shutdown on Jan. 8. (Carolyn Kaster/AP) The partial government shutdown that's now in its 18th day is putting key cyber policy priorities on hold and leaving vital operations to a bare bones staff. But the far greater long-term danger may be the blow to government cyber defenders' morale, former officials warn. With the prospect of better pay and greater job security in the private sector, more government cyber operators are likely to decamp to industry, those former officials tell me, and the smartest cybersecurity graduates will look to industry rather than government to hone their skills. That’s especially dangerous, they say, considering the government’s struggle to recruit and retain skilled workers amid a nationwide shortage of cybersecurity talent. About 20 percent of staffers are furloughed at the De

Democrats call for investigation into Trump’s iPhone use after a report that China is listening:Analysis | The Daily 202 I The Washington Post. By James Hohmann _________________________________________________________________________________ President Trump and Chinese President Xi Jinping visit the Great Hall of the People in Beijing last November. (Andrew Harnik/AP) With Breanne Deppisch and Joanie Greve THE BIG IDEA: If Democrats win the House in two weeks, it’s a safe bet that one of the oversight hearings they schedule for early next year would focus on President Trump’s use of unsecured cellphones. The matter would not likely be pursued with anywhere near the gusto that congressional Republicans investigated Hillary Clinton’s use of a private email server during her time as secretary of state. Leaders of the minority party have higher priorities . But Democratic lawmakers made clear Thursday morning that they will not ignore a New York Times report that Trump has refused to stop using iPhones in the White House, despite repeated warnings from U.S. intelligence offici

RTTNews: Morning Market Briefing.-Weekly Jobless Claims Edge Down To 444,000. May 13th 2010

Morning Market Briefing Thu May 13 09:01 2010   Commentary May 13, 2010 Stocks Poised For Lackluster Open Amid Mixed Market Sentiment - U.S. Commentary Stocks are on pace for a mixed start to Thursday's session, as a mostly upbeat jobs report continued to relieve the markets while some consternation regarding the European debt crisis remained on traders' minds. The major index futures are little changed, with the Dow futures down by 4 points. Full Article Economic News May 13, 2010 Weekly Jobless Claims Edge Down To 444,000 First-time claims for unemployment benefits showed another modest decrease in the week ended May 8th, according to a report released by the Labor Department on Thursday, although the number of claims exceeded estimates due to an upward revision to the previous week's data. Full Article May 13, 2010 Malaysia's Decade High Growth Triggers Policy Tightening Malaysia's economy grew at the fastest pace in a decade in